Frequency of potential azole drug-drug interactions and consequences of potential fluconazole drug interactions

Yu, Dong; Peterson, Josh F.; Seger, Diane L.; Gerth, William C.; Bates, David W.

doi:10.1002/pds.1073

Cited by 55 publications

(37 citation statements)

References 95 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Another retrospective cohort study assessed the frequency of pDDIs associated with fluconazole, itraconazole or ketoconazole in hospitalized patients treated for systemic fungal infections. 37 The prevalence of pDDIs was 70% in patients administered azoles; but in only 0.5% of the patients with a pDDI, was the interacting drug combination considered to have contributed to the manifestation of an ADE. 37 On the basis of our findings and comparable Figure 1 Occurrence of adverse drug events (ADEs) by causality for each of the antimycotic drugs investigated.…”

Section: Discussionmentioning

confidence: 99%

“…37 The prevalence of pDDIs was 70% in patients administered azoles; but in only 0.5% of the patients with a pDDI, was the interacting drug combination considered to have contributed to the manifestation of an ADE. 37 On the basis of our findings and comparable Figure 1 Occurrence of adverse drug events (ADEs) by causality for each of the antimycotic drugs investigated. 38 The susceptibility for ADEs is dependent on the plasma concentration of each agent, the drug formulation and inter-patient variability.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Drug interactions and adverse events associated with antimycotic drugs used for invasive aspergillosis in hematopoietic SCT

Egger

Meier

Leu

et al. 2009

Bone Marrow Transplant

View full text Add to dashboard Cite

The aim of this study was to assess the frequency of potential drug-drug interactions (pDDIs) and adverse drug events (ADEs) associated with antimycotics in hospitalized patients with hematopoietic SCT (HSCT). Of the 120 HSCT recipients evaluated, 36 received antimycotics. A total of 124 ADEs were recorded in 32 of the 36 patients treated, with 54 ADEs being possibly and 9 probably related to antimycotics. Of the treatments with amphotericin B, 93% were associated with one or more possible and 36% with probable ADEs. The corresponding figures for lipid-based amphotericin B were 100% and 7%, for voriconazole 68% and 11% and for caspofungin 70% and 0%. A total of 57 potentially severe DDIs associated with antimycotics were detected in 31 of the 36 patients. Of these, 14 DDIs were a possible cause of an ADE and 5 (4 times a combination of voriconazole with CYA and once a combination of CYA with conventional amphotericin B) were probably related. Although the prevalence of pDDIs and ADEs is high in HSCT patients, ADEs related with a high probability to treatment with antimycotics are rare. Regarding the high prevalence of pDDIs, our findings underscore the importance of close monitoring of laboratory and clinical parameters, as well as dose adjustment for critical drugs, in patients with HSCT.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Drug interactions and adverse events associated with antimycotic drugs used for invasive aspergillosis in hematopoietic SCT

Egger

Meier

Leu

et al. 2009

Bone Marrow Transplant

View full text Add to dashboard Cite

show abstract

“…16 Whether or not the missed DDIs in this study were a result of customization or complete absence from the system was not explored in this study.…”

Section: ■■ Discussionmentioning

confidence: 99%

Evaluation of the Performance of Drug-Drug Interaction Screening Software in Community and Hospital Pharmacies

Abarca

Colón

Wang³

et al. 2006

JMCP

View full text Add to dashboard Cite

harmacists play an important role in protecting the public from the dangers posed by potential drug-drug interactions (DDIs), which have been identified as an important subset of medication errors.1 They are uniquely trained to recognize medication-related problems and have the opportunity to review the medication profiles of patients in the inpatient and outpatient setting before dispensing occurs.One of the tools that pharmacists rely on to review medication profiles for DDIs is computerized screening for DDIs. Computerized screening for DDIs and other potential drug-related problems is embedded within most pharmacy computer systems that are used in community and hospital pharmacies and also is included in the prospective, online drug utilization review provided by pharmacy benefit managers. While manual review of medication regimens can be performed by pharmacists, recognition of DDIs without the use of an aid (e.g., drug interaction reference, computer program) only identifies approximately 70% of DDIs in a 2-drug regimen and the proportion decreases substantially as the number of medications increases.2 Thus, computerized DDI screening has the potential to significantly improve the recognition of potentially harmful DDIs beyond what can be achieved with manual review alone. 3Research on the performance of computerized DDI screening software and the references they are based on have found problems in the ability to provide consistent information and screen for clinically significant DDIs. [4][5][6][7][8] For example, in 2001, Hazlet et al. ABSTRACTBACKGROUND: Computerized drug-drug interaction (DDI) screening is widely used to identify potentially harmful drug combinations in the inpatient and outpatient setting.OBJECTIVE: To evaluate the performance of drug-drug interaction (DDI) screening software in identifying select clinically significant DDIs in pharmacy computer systems in community and hospital pharmacies.

show abstract

“…When a hospitalization does occur, it is usually not documented as a drug interaction, but rather as an adverse drug reaction because the drug interaction may only be one component of the reason for admission. 3,4 Although drug interactions for a select few drugs are well known, we often ignore the substantial evidence that potential interactions exist in many of the medications prescribed today.…”

mentioning

confidence: 99%

Drug Interactions of Medications Commonly Used in Diabetes

Triplitt¹

2006

Diabetes Spectrum

View full text Add to dashboard Cite

Frequency of potential azole drug-drug interactions and consequences of potential fluconazole drug interactions

Abstract: Potential fluconazole drug interactions were very frequent among hospitalized patients on systemic azole antifungal therapy, but they had few apparent clinical consequences.

Cited by 55 publications

References 95 publications

Drug interactions and adverse events associated with antimycotic drugs used for invasive aspergillosis in hematopoietic SCT

Drug interactions and adverse events associated with antimycotic drugs used for invasive aspergillosis in hematopoietic SCT

Evaluation of the Performance of Drug-Drug Interaction Screening Software in Community and Hospital Pharmacies

Drug Interactions of Medications Commonly Used in Diabetes

Contact Info

Product

Resources

About